Narcolepsy: autoimmunity, effector T cell activation due to infection, or T cell independent, major histocompatibility complex class II induced neuronal loss?

Human narcolepsy with cataplexy is a neurological disorder, which develops due to a deficiency in hypocretin producing neurons in the hypothalamus. There is a strong association with human leucocyte antigens HLA-DR2 and HLA-DQB1*0602. The disease typically starts in adolescence. Recent developments in narcolepsy research support the hypothesis of narcolepsy being an immune-mediated disease. Narcolepsy is associated with polymorphisms of the genes encoding T cell receptor alpha chain, tumour necrosis factor alpha and tumour necrosis factor receptor II. Moreover the rate of streptococcal infection is increased at onset of narcolepsy. The hallmarks of anti-self reactions in the tissue--namely upregulation of major histocompatibility antigens and lymphocyte infiltrates--are missing in the hypothalamus. These findings are questionable because they were obtained by analyses performed many years after onset of disease. In some patients with narcolepsy autoantibodies to Tribbles homolog 2, which is expressed by hypocretin neurons, have been detected recently. Immune-mediated destruction of hypocretin producing neurons may be mediated by microglia/macrophages that become activated either by autoantigen specific CD4(+) T cells or superantigen stimulated CD8(+) T cells, or independent of T cells by activation of DQB1*0602 signalling. Activation of microglia and macrophages may lead to the release of neurotoxic molecules such as quinolinic acid, which has been shown to cause selective destruction of hypocretin neurons in the hypothalamus.

[1]  M. Mühlethaler,et al.  Elevated Tribbles homolog 2-specific antibody levels in narcolepsy patients. , 2010, The Journal of clinical investigation.

[2]  T. Koepsell,et al.  Narcolepsy and streptococcal infections. , 2009, Sleep.

[3]  J. Olsen,et al.  Autoimmune disease and risk for Parkinson disease , 2009, Neurology.

[4]  H. Wiendl,et al.  CD8+ T cells and neuronal damage: direct and collateral mechanisms of cytotoxicity and impaired electrical excitability , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[5]  C. Shatz,et al.  MHC Class I: An Unexpected Role in Neuronal Plasticity , 2009, Neuron.

[6]  M. Tafti,et al.  Genetic aspects of normal and disturbed sleep. , 2009, Sleep medicine.

[7]  H. Akiyama,et al.  Absence of ubiquitinated inclusions in hypocretin neurons of patients with narcolepsy , 2009, Neurology.

[8]  J. Siegel,et al.  Localized loss of hypocretin (orexin) cells in narcolepsy without cataplexy. , 2009, Sleep.

[9]  E. Mignot,et al.  Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. , 2009, Sleep.

[10]  C. Gieger,et al.  Erratum: Narcolepsy is strongly associated with the T-cell receptor alpha locus , 2009, Nature Genetics.

[11]  G. Gao,et al.  Structural immunology and crystallography help immunologists see the immune system in action: How T and NK cells touch their ligands , 2009, IUBMB life.

[12]  P. Staeheli,et al.  Interferon-gamma prevents death of bystander neurons during CD8 T cell responses in the brain. , 2009, The American journal of pathology.

[13]  Y. Itoyama,et al.  Narcolepsy as an initial manifestation of neuromyelitis optica with antiaquaporin-4 antibody , 2009, Journal of Neurology.

[14]  Emmanuel Mignot,et al.  IGFBP3 Colocalizes with and Regulates Hypocretin (Orexin) , 2009, PloS one.

[15]  Michael W. Jackson,et al.  An Autoantibody in Narcolepsy Disrupts Colonic Migrating Motor Complexes , 2008, The Journal of Neuroscience.

[16]  J. Ting,et al.  MHC class II exacerbates demyelination in vivo independently of T cells , 2008, Journal of Neuroimmunology.

[17]  T. Proft,et al.  The bacterial superantigen and superantigen‐like proteins , 2008, Immunological reviews.

[18]  C. Baumann,et al.  No persistent effect of intravenous immunoglobulins in patients with narcolepsy with cataplexy , 2008, Journal of Neurology.

[19]  J. Dalmau,et al.  Neuronal surface antigen antibodies in limbic encephalitis , 2008, Neurology.

[20]  E. Mignot,et al.  Intravenous high-dose immunoglobulin treatment in recent onset childhood narcolepsy with cataplexy , 2008, Journal of Neurology.

[21]  E. Mignot,et al.  CSF hypocretin-1 assessment in sleep and neurological disorders , 2008, The Lancet Neurology.

[22]  T. Scammell,et al.  Do enteric neurons make hypocretin? , 2008, Regulatory Peptides.

[23]  Robert M. Plenge,et al.  Defining the Role of the MHC in Autoimmunity: A Review and Pooled Analysis , 2008, PLoS genetics.

[24]  Takeshi Sakurai,et al.  Orexin neuronal circuitry: Role in the regulation of sleep and wakefulness , 2008, Frontiers in Neuroendocrinology.

[25]  B. Jakobsen,et al.  Cutting Edge: Evidence of Direct TCR α-Chain Interaction with Superantigen1 , 2007, The Journal of Immunology.

[26]  Adriano Fontana,et al.  TNF-α suppresses the expression of clock genes by interfering with E-box-mediated transcription , 2007, Proceedings of the National Academy of Sciences.

[27]  T. Aw,et al.  Neuronal apoptosis in neurodegeneration. , 2007, Antioxidants & redox signaling.

[28]  Carla J. Shatz,et al.  Regulation of CNS synapses by neuronal MHC class I , 2007, Proceedings of the National Academy of Sciences.

[29]  Takeshi Sakurai,et al.  The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness , 2007, Nature Reviews Neuroscience.

[30]  P. Jennum,et al.  Antibodies in narcolepsy–cataplexy patient serum bind to rat hypocretin neurons , 2007, Neuroreport.

[31]  R. Wehrle,et al.  Plasma levels of tumor necrosis factor alpha and soluble tumor necrosis factor receptors in patients with narcolepsy. , 2006, Archives of internal medicine.

[32]  Oleg Gerasimenko,et al.  Tandem-Pore K+ Channels Mediate Inhibition of Orexin Neurons by Glucose , 2006, Neuron.

[33]  Susumu Tanaka,et al.  Detection of autoantibodies against hypocretin, hcrtrl, and hcrtr2 in narcolepsy: anti-Hcrt system antibody in narcolepsy. , 2006, Sleep.

[34]  R. Malenka,et al.  Synaptic scaling mediated by glial TNF-α , 2006, Nature.

[35]  P. Santamaria,et al.  CD8+ T cells in autoimmunity. , 2005, Current opinion in immunology.

[36]  S. Tufik,et al.  Clock gene polymorphisms and narcolepsy in positive and negative HLA-DQB1*0602 patients. , 2005, Brain research. Molecular brain research.

[37]  J. Siegel,et al.  Narp immunostaining of human hypocretin (orexin) neurons , 2005, Neurology.

[38]  C. Saper,et al.  Concomitant loss of dynorphin, NARP, and orexin in narcolepsy , 2005, Neurology.

[39]  C. Baumann,et al.  Hypocretins (orexins) and sleep–wake disorders , 2005, The Lancet Neurology.

[40]  D. Mattey,et al.  Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis , 2005, Arthritis research & therapy.

[41]  Yujin Zhang,et al.  Identification of tribbles homolog 2 as an autoantigen in autoimmune uveitis by phage display. , 2005, Molecular Immunology.

[42]  E. Dropcho Update on paraneoplastic syndromes , 2005, Current opinion in neurology.

[43]  V. Pankratz,et al.  Analysis of hypocretin (orexin) antibodies in patients with narcolepsy. , 2005, Sleep.

[44]  R. Malenka,et al.  Differential Regulation of AMPA Receptor and GABA Receptor Trafficking by Tumor Necrosis Factor-α , 2005, The Journal of Neuroscience.

[45]  T. Hökfelt,et al.  A role for MHC class I molecules in synaptic plasticity and regeneration of neurons after axotomy. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[46]  My Zhu,et al.  Direct evidence for predation on trilobites in the Cambrian , 2004, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[47]  M. Rosenfeld,et al.  Clinical analysis of anti-Ma2-associated encephalitis. , 2004, Brain : a journal of neurology.

[48]  T. Pollmächer,et al.  Oligoclonal bands and specific antibody indices in human narcolepsy , 2004 .

[49]  M. Coussons‐Read,et al.  Exploring the cytokine and endocrine involvement in narcolepsy , 2004, Brain, Behavior, and Immunity.

[50]  Carla J. Shatz,et al.  Immune signalling in neural development, synaptic plasticity and disease , 2004, Nature Reviews Neuroscience.

[51]  F. Zipp,et al.  Direct Impact of T Cells on Neurons Revealed by Two-Photon Microscopy in Living Brain Tissue , 2004, The Journal of Neuroscience.

[52]  Arne Svejgaard,et al.  Crystal structure of HLA-DQ0602 that protects against type 1 diabetes and confers strong susceptibility to narcolepsy , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[53]  A. Akaike,et al.  Excitotoxic degeneration of hypothalamic orexin neurons in slice culture , 2004, Neurobiology of Disease.

[54]  Yi Guo,et al.  Crystal structure of Mycoplasma arthritidis mitogen complexed with HLA-DR1 reveals a novel superantigen fold and a dimerized superantigen-MHC complex. , 2004, Structure.

[55]  E. Mignot,et al.  Hypocretin-1 CSF levels in anti-Ma2 associated encephalitis , 2004, Neurology.

[56]  S. Swedo,et al.  Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea , 2003, Nature Medicine.

[57]  Jon T. Willie,et al.  Distinct Narcolepsy Syndromes in Orexin Receptor-2 and Orexin Null Mice Molecular Genetic Dissection of Non-REM and REM Sleep Regulatory Processes , 2003, Neuron.

[58]  D. Rujescu,et al.  TNFA promoter polymorphisms and narcolepsy. , 2003, Tissue antigens.

[59]  Takeshi Sakurai,et al.  Hypocretin/Orexin Excites Hypocretin Neurons via a Local Glutamate Neuron—A Potential Mechanism for Orchestrating the Hypothalamic Arousal System , 2002, Neuron.

[60]  K. Akassoglou,et al.  Glial expression of tumor necrosis factor in transgenic animals: How do these models reflect the “normal situation”? , 2001, Glia.

[61]  T. Stone Kynurenines in the CNS: from endogenous obscurity to therapeutic importance , 2001, Progress in Neurobiology.

[62]  K. Tokunaga,et al.  Allele-specific binding of the ubiquitous transcription factor OCT-1 to the functional single nucleotide polymorphism (SNP) sites in the tumor necrosis factor-alpha gene (TNFA) promoter , 2001, Genes and Immunity.

[63]  N Risch,et al.  Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. , 2001, American journal of human genetics.

[64]  K. Tokunaga,et al.  Case-control study with narcoleptic patients and healthy controls who, like the patients, possess both HLA-DRB1*1501 and -DQB1*0602. , 2001, Tissue antigens.

[65]  K. Tokunaga,et al.  Haplotype analyses with the human leucocyte antigen and tumour necrosis factor‐alpha genes in narcolepsy families , 2001, Psychiatry and clinical neurosciences.

[66]  Sebastiaan Overeem,et al.  A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains , 2000, Nature Medicine.

[67]  Michael Aldrich,et al.  Reduced Number of Hypocretin Neurons in Human Narcolepsy , 2000, Neuron.

[68]  J. Naismith,et al.  TNFα and the TNF receptor superfamily: Structure‐function relationship(s) , 2000, Microscopy research and technique.

[69]  T. Arinami,et al.  Linkage of human narcolepsy with HLA association to chromosome 4p13-q21. , 2000, Genomics.

[70]  Sebastiaan Overeem,et al.  Hypocretin (orexin) deficiency in human narcolepsy , 2000, The Lancet.

[71]  Emmanuel Mignot,et al.  The Sleep Disorder Canine Narcolepsy Is Caused by a Mutation in the Hypocretin (Orexin) Receptor 2 Gene , 1999, Cell.

[72]  Jon T. Willie,et al.  Narcolepsy in orexin Knockout Mice Molecular Genetics of Sleep Regulation , 1999, Cell.

[73]  A. Faden,et al.  Early neuronal expression of tumor necrosis factor-α after experimental brain injury contributes to neurological impairment , 1999, Journal of Neuroimmunology.

[74]  F. Holsboer,et al.  In vivo and in vitro immune variables in patients with narcolepsy and HLA-DR2 matched controls , 1998, Neurology.

[75]  E. Mignot,et al.  Genetic and familial aspects of narcolepsy , 1998, Neurology.

[76]  J. Ting,et al.  Differential regulation of cytokine-induced major histocompatibility complex class II expression and nitric oxide release in rat microglia and astrocytes by effectors of tyrosine kinase, protein kinase C, and cAMP , 1997, Journal of Neuroimmunology.

[77]  J. Tschopp,et al.  Neurons induced to express major histocompatibility complex class I antigen are killed via the perforin and not the Fas (APO‐1/CD95) pathway , 1996, European journal of immunology.

[78]  R. L. Baldwin,et al.  Structural changes of tumor necrosis factor alpha associated with membrane insertion and channel formation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[79]  L. Mucke,et al.  Consequences of cytotoxic T lymphocyte interaction with major histocompatibility complex class I-expressing neurons in vivo , 1995, The Journal of experimental medicine.

[80]  H. Neumann,et al.  Induction of MHC class I genes in neurons. , 1995, Science.

[81]  Michael J. Grusby,et al.  Absence of MHC class ii molecules reduces CNS demyelination, microglial/macrophage infiltration, and twitching in murine globoid cell leukodystrophy , 1994, Cell.

[82]  J. Pablos,et al.  Narcolepsy in systemic lupus erythematosus. , 1993, The Journal of rheumatology.

[83]  K. Frei,et al.  Macrophage‐induced cytotoxicity of N‐methyl‐D‐aspartate receptor positive neurons involves excitatory amino acids rather than reactive oxygen intermediates and cytokines , 1992, European journal of immunology.

[84]  Emmanuel Mignot,et al.  DQ (rather than DR) gene marks susceptibility to narcolepsy , 1992, The Lancet.

[85]  R. L. Baldwin,et al.  Formation of ion-permeable channels by tumor necrosis factor-alpha. , 1992, Science.

[86]  M. Cuénod,et al.  Murine brain macrophages induce NMDA receptor mediated neurotoxicity in vitro by secreting glutamate , 1991, Neuroscience Letters.

[87]  J. Ragoussis,et al.  Map of the human MHC. , 1991, Immunology today.

[88]  L. Mucke,et al.  Viral persistence in neurons explained by lack of major histocompatibility class I expression. , 1991, Science.

[89]  M. Billiard,et al.  CSF immune variables in patients with narcolepsy , 1990, Acta neurologica Scandinavica.

[90]  G. Mueller‐Eckhardt,et al.  Is there an infectious origin of narcolepsy? , 1990, The Lancet.

[91]  M. Shin,et al.  Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[92]  R. Zinkernagel,et al.  On the cellular source and function of interleukin 6 produced in the central nervous system in viral diseases , 1989, European journal of immunology.

[93]  M. Mitler,et al.  HLA-DR2 association with excessive somnolence in narcolepsy does not generalize to sleep apnea and is not accompanied by systemic autoimmune abnormalities. , 1988, Clinical immunology and immunopathology.

[94]  R. Vaughan,et al.  GENETIC MARKERS IN NARCOLEPSY , 1984, The Lancet.

[95]  C. Guilleminault,et al.  Narcolepsy. Diagnosis and treatment. , 1976, Primary care.

[96]  D. Mueller Mechanisms maintaining peripheral tolerance , 2010, Nature Immunology.

[97]  R. Peixoto,et al.  Necrotic neurons enhance microglial neurotoxicity through induction of glutaminase by a MyD88-dependent pathway , 2008, Journal of Neuroinflammation.

[98]  Adriano Fontana,et al.  TNF-alpha suppresses the expression of clock genes by interfering with E-box-mediated transcription. , 2007, Proceedings of the National Academy of Sciences of the United States of America.

[99]  Gerald van Belle,et al.  The epidemiology of narcolepsy. , 2007, Sleep.

[100]  B. Jakobsen,et al.  Cutting edge: Evidence of direct TCR alpha-chain interaction with superantigen. , 2007, Journal of immunology.

[101]  S. Overeem,et al.  Short communication Immunohistochemical screening for autoantibodies against lateral hypothalamic neurons in human narcolepsy , 2006 .

[102]  R. Malenka,et al.  Synaptic scaling mediated by glial TNF-alpha. , 2006, Nature.

[103]  P. Scheurich,et al.  Tumor necrosis factor signaling , 2003, Cell Death and Differentiation.

[104]  R. Malenka,et al.  Control of synaptic strength by glial TNFalpha. , 2002, Science.

[105]  P A Dekker-de Kiefte,et al.  Diagnosis and Treatment , 2020, Diabetes.

[106]  J. Ragoussis,et al.  Map of the human MHC. , 1991, Immunology today.